RA Mediated T-reg Differentiation - Revision history

Michal Harel at 09:28, 12 January 2023

Michal Harel — Thu, 12 Jan 2023 09:28:16 GMT

←Older revision		Revision as of 09:28, 12 January 2023
Line 2:		Line 2:
	==Introduction==		==Introduction==
	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the [[Nuclear receptors\|nuclear receptor family]], and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>		T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the [[Nuclear receptors\|nuclear receptor family]], and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>
		+
		+	See also [[Intracellular receptors]]

	==Ligand Binding Domain==		==Ligand Binding Domain==

Alexander Berchansky at 18:51, 25 January 2021

Alexander Berchansky — Mon, 25 Jan 2021 18:51:29 GMT

←Older revision		Revision as of 18:51, 25 January 2021
Line 1:		Line 1:
	<StructureSection load='1dkf' size='400' side='right' scene='' caption='Mouse retinoid X receptor-α ligand-binding domain (grey) complex with retinoic acid receptor-α ligand-binding domain (green), oleic acid and benzoic acid derivative (PDB code [[1dkf]]). '>		<StructureSection load='1dkf' size='400' side='right' scene='' caption='Mouse retinoid X receptor-α ligand-binding domain (grey) complex with retinoic acid receptor-α ligand-binding domain (green), oleic acid and benzoic acid derivative (PDB code [[1dkf]]). '>
	==Introduction==		==Introduction==
-	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>	+	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the [[Nuclear receptors\|nuclear receptor family]], and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>

	==Ligand Binding Domain==		==Ligand Binding Domain==

Michal Harel at 07:57, 1 January 2015

Michal Harel — Thu, 01 Jan 2015 07:57:51 GMT

←Older revision		Revision as of 07:57, 1 January 2015
Line 52:		Line 52:

	==3D structures of RXR and RAR==		==3D structures of RXR and RAR==
-	[[Retinoid X receptor]]	+	[[Retinoid X receptor]]<br />
	[[Retinoic acid receptor]]		[[Retinoic acid receptor]]
	</StructureSection>		</StructureSection>
	==References==		==References==
	<references />		<references />

Michal Harel at 07:57, 1 January 2015

Michal Harel — Thu, 01 Jan 2015 07:57:14 GMT

←Older revision		Revision as of 07:57, 1 January 2015
Line 50:		Line 50:
	==Biological Significance==		==Biological Significance==
	Since T-regulatory cells are so highly regulated in the body, elucidating the exact mechanism of activation can show how these immune processes work, and use them in the treatment of disease. Two clear mechanisms of regulation arise from the studies, both which are related to the heterodimer itself. First, the ligand specificity for RA in both molecules allows for specific signaling of these molecules. RA is not normally expressed in cells, and therefore will limit when this heterodimer is activated. Likewise, the propensity for the heterodimer to associate with DR-5 repeats limits the number of genes it will activate to a select few. All of this in addition to the other cytokines necessary, TGF-β and IL-2, show the complex mechanisms regulating the differentiation of T-helper cells into T-regulatory cells.		Since T-regulatory cells are so highly regulated in the body, elucidating the exact mechanism of activation can show how these immune processes work, and use them in the treatment of disease. Two clear mechanisms of regulation arise from the studies, both which are related to the heterodimer itself. First, the ligand specificity for RA in both molecules allows for specific signaling of these molecules. RA is not normally expressed in cells, and therefore will limit when this heterodimer is activated. Likewise, the propensity for the heterodimer to associate with DR-5 repeats limits the number of genes it will activate to a select few. All of this in addition to the other cytokines necessary, TGF-β and IL-2, show the complex mechanisms regulating the differentiation of T-helper cells into T-regulatory cells.
		+
		+	==3D structures of RXR and RAR==
		+	[[Retinoid X receptor]]
		+	[[Retinoic acid receptor]]
	</StructureSection>		</StructureSection>
	==References==		==References==
	<references />		<references />

Michal Harel at 07:49, 1 January 2015

Michal Harel — Thu, 01 Jan 2015 07:49:46 GMT

←Older revision		Revision as of 07:49, 1 January 2015
Line 1:		Line 1:
-	<StructureSection load='1dkf' size='400' side='right' scene='' caption='Mouse retinoid X receptor-α ligand-binding domain (grey) complex with retinoic acid receptor-α ligand-binding domain (green) (PDB code [[1dkf]]). '>	+	<StructureSection load='1dkf' size='400' side='right' scene='' caption='Mouse retinoid X receptor-α ligand-binding domain (grey) complex with retinoic acid receptor-α ligand-binding domain (green), oleic acid and benzoic acid derivative (PDB code [[1dkf]]). '>
	==Introduction==		==Introduction==
	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>		T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>

Michal Harel at 07:48, 1 January 2015

Michal Harel — Thu, 01 Jan 2015 07:48:31 GMT

←Older revision		Revision as of 07:48, 1 January 2015
Line 1:		Line 1:
-	<StructureSection load='1dkf' size='400' side='right' scene='' caption=''>	+	<StructureSection load='1dkf' size='400' side='right' scene='' caption='Mouse retinoid X receptor-α ligand-binding domain (grey) complex with retinoic acid receptor-α ligand-binding domain (green) (PDB code [[1dkf]]). '>
	==Introduction==		==Introduction==
	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>		T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>

Alexander Berchansky at 13:07, 24 November 2014

Alexander Berchansky — Mon, 24 Nov 2014 13:07:33 GMT

←Older revision		Revision as of 13:07, 24 November 2014
Line 2:		Line 2:
	==Introduction==		==Introduction==
	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>		T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>
-	~~<scene name='51/519788/Cv/1'>RARα-RXRα interaction</scene> (PDB entry [[1dkf]]).~~	+
-		+
	==Ligand Binding Domain==		==Ligand Binding Domain==
		+	<scene name='51/519788/Cv/1'>RARα-RXRα interaction</scene> (PDB entry [[1dkf]]).
	The Ligand binding domain for each piece of the dimer has a nearly identical structure of an <scene name='RA_Mediated_T-reg_Differentiaition/Alpha-helical_domains/2'>Tα-helical sandwich</scene>. These alpha helices form a total of 12 domains per protein (referred to as H1-12), with an additional 2 beta sheets as well. Additionally, the α-helical sandwich formed has been shown to bind All-Trans Retinoic Acid (ATRA), the isomer of RA used by the body. Both monomers contain two regions of activity, the <scene name='RA_Mediated_T-reg_Differentiaition/Dimerization_interface/3'>dimerization interface</scene> and the <scene name='RA_Mediated_T-reg_Differentiaition/Ligand_binding_pockets/1'> ligand binding pocket </scene>.<ref> PMID: 10882070 </ref>		The Ligand binding domain for each piece of the dimer has a nearly identical structure of an <scene name='RA_Mediated_T-reg_Differentiaition/Alpha-helical_domains/2'>Tα-helical sandwich</scene>. These alpha helices form a total of 12 domains per protein (referred to as H1-12), with an additional 2 beta sheets as well. Additionally, the α-helical sandwich formed has been shown to bind All-Trans Retinoic Acid (ATRA), the isomer of RA used by the body. Both monomers contain two regions of activity, the <scene name='RA_Mediated_T-reg_Differentiaition/Dimerization_interface/3'>dimerization interface</scene> and the <scene name='RA_Mediated_T-reg_Differentiaition/Ligand_binding_pockets/1'> ligand binding pocket </scene>.<ref> PMID: 10882070 </ref>

Alexander Berchansky at 13:06, 24 November 2014

Alexander Berchansky — Mon, 24 Nov 2014 13:06:02 GMT

←Older revision		Revision as of 13:06, 24 November 2014
Line 34:		Line 34:

	The <scene name='RA_Mediated_T-reg_Differentiaition/Rxr-ligand_binding_pocket/1'>RXR-alpha binding pocket</scene> is comprised of 16 primarily hydrophobic residues, found on the H3, H5, H7, H11, and L11-12 domains. The ligand used in the crystal, Oleic Acid, is similar to RA, and RA is capable of binding to the RXRα pocket.<ref> PMID: 10882070 </ref>		The <scene name='RA_Mediated_T-reg_Differentiaition/Rxr-ligand_binding_pocket/1'>RXR-alpha binding pocket</scene> is comprised of 16 primarily hydrophobic residues, found on the H3, H5, H7, H11, and L11-12 domains. The ligand used in the crystal, Oleic Acid, is similar to RA, and RA is capable of binding to the RXRα pocket.<ref> PMID: 10882070 </ref>
-
-	</StructureSection>
-	<StructureSection load='1BY4' size='350' side='right' caption='Crystal structure of RXRα-DNA complex (PDB entry [[1by4]])' scene=''>

	==DNA Binding Domain==		==DNA Binding Domain==
		+	<scene name='51/519788/Cv/2'>Crystal structure of RXRα-DNA complex</scene> (PDB entry [[1by4]]).
	When RXRα homodimers assemble on DNA, they form a four poplypeptide complex assembled via head to tail interactions along DR-1 repeated sequences. The		When RXRα homodimers assemble on DNA, they form a four poplypeptide complex assembled via head to tail interactions along DR-1 repeated sequences. The
	<scene name='RA_Mediated_T-reg_Differentiaition/Rxr_dbd_alpha_helices/1'>alpha helical</scene> structures of the polypeptides sit in the major grooves of the DNA chain, allowing for interaction with specific bases, giving a sequence specificity for the protein. The two <scene name='RA_Mediated_T-reg_Differentiaition/Rxr_dbd_zn_domains/2'>Zinc containing domains</scene> do not alter their configuration upon DNA binding, but are used to guide the DNA into the correct position. Upon binding to DNA, the C-terminal end of the protein, referred to as the <scene name='RA_Mediated_T-reg_Differentiaition/Rxr_dbd_t-box/1'> "T-box" </scene> alters its conformation from alpha helical to an extended conformation. This extended conformation allows Glu74 to move away from the DNA binding pocket and moves it so it interacts with the Zn(II) domain of the next polypeptide. <ref> PMID: 10669605 </ref>		<scene name='RA_Mediated_T-reg_Differentiaition/Rxr_dbd_alpha_helices/1'>alpha helical</scene> structures of the polypeptides sit in the major grooves of the DNA chain, allowing for interaction with specific bases, giving a sequence specificity for the protein. The two <scene name='RA_Mediated_T-reg_Differentiaition/Rxr_dbd_zn_domains/2'>Zinc containing domains</scene> do not alter their configuration upon DNA binding, but are used to guide the DNA into the correct position. Upon binding to DNA, the C-terminal end of the protein, referred to as the <scene name='RA_Mediated_T-reg_Differentiaition/Rxr_dbd_t-box/1'> "T-box" </scene> alters its conformation from alpha helical to an extended conformation. This extended conformation allows Glu74 to move away from the DNA binding pocket and moves it so it interacts with the Zn(II) domain of the next polypeptide. <ref> PMID: 10669605 </ref>
Line 48:		Line 46:
	=== DR-5 Specificity ===		=== DR-5 Specificity ===
	RXRα/RARα homodimers have not yet been crystallized on DNA, but have been shown to associate with extended DR-5 tandem repeats. The sequence of this DR-5 repeat is AGGTCA-nnnnn-AGGTCA. Additonally, when incubated with retinoic acid, cells expressing RARα showed high expression of genes located downstream of DR-5 tandem repeats. <ref> PMID: 1648450 </ref>		RXRα/RARα homodimers have not yet been crystallized on DNA, but have been shown to associate with extended DR-5 tandem repeats. The sequence of this DR-5 repeat is AGGTCA-nnnnn-AGGTCA. Additonally, when incubated with retinoic acid, cells expressing RARα showed high expression of genes located downstream of DR-5 tandem repeats. <ref> PMID: 1648450 </ref>
-	~~</StructureSection>~~	+

	==Biological Significance==		==Biological Significance==
	Since T-regulatory cells are so highly regulated in the body, elucidating the exact mechanism of activation can show how these immune processes work, and use them in the treatment of disease. Two clear mechanisms of regulation arise from the studies, both which are related to the heterodimer itself. First, the ligand specificity for RA in both molecules allows for specific signaling of these molecules. RA is not normally expressed in cells, and therefore will limit when this heterodimer is activated. Likewise, the propensity for the heterodimer to associate with DR-5 repeats limits the number of genes it will activate to a select few. All of this in addition to the other cytokines necessary, TGF-β and IL-2, show the complex mechanisms regulating the differentiation of T-helper cells into T-regulatory cells.		Since T-regulatory cells are so highly regulated in the body, elucidating the exact mechanism of activation can show how these immune processes work, and use them in the treatment of disease. Two clear mechanisms of regulation arise from the studies, both which are related to the heterodimer itself. First, the ligand specificity for RA in both molecules allows for specific signaling of these molecules. RA is not normally expressed in cells, and therefore will limit when this heterodimer is activated. Likewise, the propensity for the heterodimer to associate with DR-5 repeats limits the number of genes it will activate to a select few. All of this in addition to the other cytokines necessary, TGF-β and IL-2, show the complex mechanisms regulating the differentiation of T-helper cells into T-regulatory cells.
-		+	</StructureSection>
	==References==		==References==
	<references />		<references />

Alexander Berchansky at 13:02, 24 November 2014

Alexander Berchansky — Mon, 24 Nov 2014 13:02:36 GMT

←Older revision		Revision as of 13:02, 24 November 2014
Line 1:		Line 1:
-	<StructureSection load='' size='400' side='right' scene='' caption=''>	+	<StructureSection load='1dkf' size='400' side='right' scene='' caption=''>
	==Introduction==		==Introduction==
	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>		T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>
	<scene name='51/519788/Cv/1'>RARα-RXRα interaction</scene> (PDB entry [[1dkf]]).		<scene name='51/519788/Cv/1'>RARα-RXRα interaction</scene> (PDB entry [[1dkf]]).
-	~~RARα-RXRα interaction (PDB entry [[1dkf]])~~	+
	==Ligand Binding Domain==		==Ligand Binding Domain==
	The Ligand binding domain for each piece of the dimer has a nearly identical structure of an <scene name='RA_Mediated_T-reg_Differentiaition/Alpha-helical_domains/2'>Tα-helical sandwich</scene>. These alpha helices form a total of 12 domains per protein (referred to as H1-12), with an additional 2 beta sheets as well. Additionally, the α-helical sandwich formed has been shown to bind All-Trans Retinoic Acid (ATRA), the isomer of RA used by the body. Both monomers contain two regions of activity, the <scene name='RA_Mediated_T-reg_Differentiaition/Dimerization_interface/3'>dimerization interface</scene> and the <scene name='RA_Mediated_T-reg_Differentiaition/Ligand_binding_pockets/1'> ligand binding pocket </scene>.<ref> PMID: 10882070 </ref>		The Ligand binding domain for each piece of the dimer has a nearly identical structure of an <scene name='RA_Mediated_T-reg_Differentiaition/Alpha-helical_domains/2'>Tα-helical sandwich</scene>. These alpha helices form a total of 12 domains per protein (referred to as H1-12), with an additional 2 beta sheets as well. Additionally, the α-helical sandwich formed has been shown to bind All-Trans Retinoic Acid (ATRA), the isomer of RA used by the body. Both monomers contain two regions of activity, the <scene name='RA_Mediated_T-reg_Differentiaition/Dimerization_interface/3'>dimerization interface</scene> and the <scene name='RA_Mediated_T-reg_Differentiaition/Ligand_binding_pockets/1'> ligand binding pocket </scene>.<ref> PMID: 10882070 </ref>
Line 34:		Line 34:

	The <scene name='RA_Mediated_T-reg_Differentiaition/Rxr-ligand_binding_pocket/1'>RXR-alpha binding pocket</scene> is comprised of 16 primarily hydrophobic residues, found on the H3, H5, H7, H11, and L11-12 domains. The ligand used in the crystal, Oleic Acid, is similar to RA, and RA is capable of binding to the RXRα pocket.<ref> PMID: 10882070 </ref>		The <scene name='RA_Mediated_T-reg_Differentiaition/Rxr-ligand_binding_pocket/1'>RXR-alpha binding pocket</scene> is comprised of 16 primarily hydrophobic residues, found on the H3, H5, H7, H11, and L11-12 domains. The ligand used in the crystal, Oleic Acid, is similar to RA, and RA is capable of binding to the RXRα pocket.<ref> PMID: 10882070 </ref>
-

	</StructureSection>		</StructureSection>
-
	<StructureSection load='1BY4' size='350' side='right' caption='Crystal structure of RXRα-DNA complex (PDB entry [[1by4]])' scene=''>		<StructureSection load='1BY4' size='350' side='right' caption='Crystal structure of RXRα-DNA complex (PDB entry [[1by4]])' scene=''>

Alexander Berchansky at 12:59, 24 November 2014

Alexander Berchansky — Mon, 24 Nov 2014 12:59:55 GMT

←Older revision		Revision as of 12:59, 24 November 2014
Line 1:		Line 1:
		+	<StructureSection load='' size='400' side='right' scene='' caption=''>
	==Introduction==		==Introduction==
-	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>	+	T-regulatory cells (T-regs) are a small subset of CD4+ T-cells that exhibit strong down regulation of immune system activity in their local environment. They are distinguished from other CD4+ T-cells by the expression of FOXP3, a gene regulator. <ref> PMID: 19410687 </ref> The exact mechanisms used by T-regs to down regulate the immune system has not yet been clearly elucidated. These cells have been shown to differentiate from CD4+ T-helper cells upon activation and exposure to the following cytokines: tumor growth factor β (TGF-β), Interleukin-2 (IL-2) and retinoic acid (RA). <ref> PMID: 21839265 </ref> Both TGF-β and IL-2 are used in other immune system differentiation, however, RA has been shown to bias T-cells to the T-reg phenotype. <ref> PMID: 21839265 </ref> When acting upon T-reg cells, RA acts as the ligand for the Retinoic Acid Receptor-α (RARα) / Retinoid X Receptor-α (RXRα) heterodimer. This heterodimer is of the nuclear receptor family, and each chain consists of the same three part structure: a Ligand binding domain (LBD), a DNA binding domain (DBD), and a hinge region connecting the two binding domains. <ref> PMID: 10406480 </ref>
-	<~~StructureSection load~~='~~1dkf' size='350' side='left' caption=~~'RARα-RXRα interaction (PDB entry [[1dkf]])~~' scene=''>~~	+	<scene name='51/519788/Cv/1'>RARα-RXRα interaction</scene> (PDB entry [[1dkf]]).
		+	RARα-RXRα interaction (PDB entry [[1dkf]])
	==Ligand Binding Domain==		==Ligand Binding Domain==
	The Ligand binding domain for each piece of the dimer has a nearly identical structure of an <scene name='RA_Mediated_T-reg_Differentiaition/Alpha-helical_domains/2'>Tα-helical sandwich</scene>. These alpha helices form a total of 12 domains per protein (referred to as H1-12), with an additional 2 beta sheets as well. Additionally, the α-helical sandwich formed has been shown to bind All-Trans Retinoic Acid (ATRA), the isomer of RA used by the body. Both monomers contain two regions of activity, the <scene name='RA_Mediated_T-reg_Differentiaition/Dimerization_interface/3'>dimerization interface</scene> and the <scene name='RA_Mediated_T-reg_Differentiaition/Ligand_binding_pockets/1'> ligand binding pocket </scene>.<ref> PMID: 10882070 </ref>		The Ligand binding domain for each piece of the dimer has a nearly identical structure of an <scene name='RA_Mediated_T-reg_Differentiaition/Alpha-helical_domains/2'>Tα-helical sandwich</scene>. These alpha helices form a total of 12 domains per protein (referred to as H1-12), with an additional 2 beta sheets as well. Additionally, the α-helical sandwich formed has been shown to bind All-Trans Retinoic Acid (ATRA), the isomer of RA used by the body. Both monomers contain two regions of activity, the <scene name='RA_Mediated_T-reg_Differentiaition/Dimerization_interface/3'>dimerization interface</scene> and the <scene name='RA_Mediated_T-reg_Differentiaition/Ligand_binding_pockets/1'> ligand binding pocket </scene>.<ref> PMID: 10882070 </ref>